구조모아 (StructureMoa)항암 chemical structure spider web
방문타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | TCR (E7 T Cell Receptor, E7 T Cell Receptor (TCR)) Iovance Biotherapeutics, Inc.·Squamous Lntraepithelial Lesions o… 124 trials |
|---|---|
Overview Program | E7 T Cell Receptor (TCR) |
Overview Company | Iovance Biotherapeutics, Inc. |
Overview Modality | CGT |
Overview Target | Squamous Lntraepithelial Lesions of Vulv |
Overview Indication | Uterine Cervical Neoplasms |
Overview Phase | PHASE_2 |
Overview Status | DISCONTINUED |
Overview Content status | Standard Database |
Overview Data Confidence | Data Confidence · Medium |
Overview Development Signal | Development Signal · Emerging |
Overview Approval status | Investigational |
Technology Vector | AAV delivery of FOXN1, AIRE, chemokines, and stromal-support pathways |
MoA Mechanism | , using healthy donor peripheral blood mononuclear cells (PBMC) and MDS patient PBMC and bone marrow samples |
MoA Biomarker | PD-1 treatment in shaping tumor-regional CD39 + CD8 + T cells high |
PK/PD Species | Mouse |
PK/PD Animal (cat.) | Mouse, In vitro |
PK/PD Experiment | PD |
Toxicology Species | Mouse |
Toxicology Animal (cat.) | Mouse, In vitro |
Toxicology Major finding | pneumonitis |
Toxicology CRS | Reported |
Clinical Safety signal | pneumonitis |
Clinical Reported PFS | 131 |
Clinical Reported OS | 154 |
Clinical Result source | ClinicalTrials.gov NCT01970527 |
Clinical Program phase | PHASE_2 |
Clinical Trial activity | No active/completed counts |
Clinical Trial ref | NCT01970527 |
타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | TCR (E7 T Cell Receptor, E7 T Cell Receptor (TCR)) Iovance Biotherapeutics, Inc.·Squamous Lntraepithelial Lesions o… 124 trials |
|---|---|
Overview Program | E7 T Cell Receptor (TCR) |
Overview Company | Iovance Biotherapeutics, Inc. |
Overview Modality | CGT |
Overview Target | Squamous Lntraepithelial Lesions of Vulv |
Overview Indication | Uterine Cervical Neoplasms |
Overview Phase | PHASE_2 |
Overview Status | DISCONTINUED |
Overview Content status | Standard Database |
Overview Data Confidence | Data Confidence · Medium |
Overview Development Signal | Development Signal · Emerging |
Overview Approval status | Investigational |
Technology Vector | AAV delivery of FOXN1, AIRE, chemokines, and stromal-support pathways |
MoA Mechanism | , using healthy donor peripheral blood mononuclear cells (PBMC) and MDS patient PBMC and bone marrow samples |
MoA Biomarker | PD-1 treatment in shaping tumor-regional CD39 + CD8 + T cells high |
PK/PD Species | Mouse |
PK/PD Animal (cat.) | Mouse, In vitro |
PK/PD Experiment | PD |
Toxicology Species | Mouse |
Toxicology Animal (cat.) | Mouse, In vitro |
Toxicology Major finding | pneumonitis |
Toxicology CRS | Reported |
Clinical Safety signal | pneumonitis |
Clinical Reported PFS | 131 |
Clinical Reported OS | 154 |
Clinical Result source | ClinicalTrials.gov NCT01970527 |
Clinical Program phase | PHASE_2 |
Clinical Trial activity | No active/completed counts |
Clinical Trial ref | NCT01970527 |
추천 비교
추천 비교